DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1α in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX

Molecular and Cellular Biology

Volumn 24, Issue 13, 2004, Pages 5757-5766

  Kaluzová, Milota ^a,b   Kaluz, Stefan ^a,b   Lerman, Michael I ^c   Stanbridge, Eric J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b INSTITUTE OF VIROLOGY   (Slovakia)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE; CARBONATE DEHYDRATASE IX; DNA; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MITOMYCIN C; PROTEASOME; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CELL HYPOXIA; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA DAMAGE; ENZYME REGULATION; GENE OVEREXPRESSION; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN STABILITY; STEADY STATE;

ANOXIA; ANTIGENS, NEOPLASM; CARBONIC ANHYDRASES; CELL LINE, TUMOR; CYSTEINE ENDOPEPTIDASES; DNA DAMAGE; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOMYCIN; PROMOTER REGIONS (GENETICS); TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

MINK CELL FOCUS-FORMING VIRUS;

EID: 2942733275     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.24.13.5757-5766.2004     Document Type: Article

References (52)

1. Achison, M., and T. R. Hupp. 2003. Hypoxia attenuates the p53 response to cellular damage. Oncogene 22:3431-3440.
2. Agani, F., D. G. Kirsch, S. L. Friedman, M. B. Kastan, and G. L. Semenza. 1997. p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene. Cancer Res. 57:4474-4477.
3. Airley, R. E., J. Loncaster, J. A. Raleigh, A. L. Harris, S. E. Davidson, R. D. Hunter, C. M. L. West, and I. J. Stratford. 2003. Glut-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int. J. Cancer 104:85-91.
4. Arany, Z., L. E. Huang, R. Eckner, S. Bhattacharya, C. Jiang, M. A. Goldberg, H. F. Bunn, and D. M. Livingston. 1996. An essential role for p300/CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 93:12969-12973.
5. Ashcroft, M., Y. Taya, and K. H. Vousden. 2000. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20:3224-3233.
6. Bai, J., and A. I. Cederbaum. 2003. Catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents by accelerating the degradation of p53. J. Biol. Chem. 278:4660-4667.
7. Blagosklonny, M. V., W. G. An, L. Y. Romanova, J. Trepel, T. Fojo, and L. Neckers. 1998. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273:1995-11998.
8. Brown, J. M., and A. J. Giaccia. 1998. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res. 58:1408-1416.
9. Bui, M. H. T., D. Seligson, K. Han, A. J. Pantuck, F. J. Dorey, Y. Huang, S. Horvath, B. C. Leibovich, S. Chopra, S.-Y. Liao, E. Stanbridge, M. I. Lerman, A. Palotie, R. A. Figlin, and A. S. Belldegrun. 2003. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin. Cancer Res. 9:802-811.
10. 2 arrest after DNA damage. Science (Washington, D.C.) 282:1497-1501.
11. Chen, X., L. J. Ko, L. Jayaraman, and C. Prives. 1996. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. 10:2438-2451.
12. Chen, D., M. Li, J. Luo., and W. Gu. 2003. Direct interactions between HIF-1α and mdm2 modulate p53 function. J. Biol. Chem. 278:13595-13598.
13. Divgi, C. R., N. H. Bander, A. M. Scott, J. A. O'Donoghue, G. Sgouros, S. Welt, R. D. Finn, F. Morrissey, P. Capitelli, J. M. Williams, D. Deland, A. Nakhre, E. Oosterwijk, S. Gulec, M. C. Graham, S. M. Larson, and L. J. Old. 1998. Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal carcinoma. Clin. Cancer Res. 4:2729-2739.
14. Giaccia, A. J., and M. B. Kastan. 1998. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 12:2973-2983.
15. Giatromanolaki, A., M. I. Koukourakis, E. Sivridis, J. Pastorek, C. C. Wykoff, K. C. Gatter, and A. L. Harris. 2001. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 61:7992-7998.
16. Girnita, L., A. Girnita, and O. Larsson. 2003. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. USA 100:8247-8252.
17. Graeber, T. G., C. Osmanian, T. Jacks, D. E. Housman, C. J. Koch, S. W. Lowe, and A. J. Giaccia. 1996. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91.
18. Hammond, E. M., N. C. Denko, M. J. Dorie, R. T. Abraham, and A. J. Giaccia. 2002. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22:1834-1843.
19. Harris, A. L. 2002. Hypoxia-a key regulatory factor in tumor growth. Nat. Rev. Cancer 2:38-47.
20. Hollstein, M., D. Sidransky, B. Vogelstein, and C. C. Harris. 1991. p53 mutations in human cancers. Science 253:49-53.
21. Isaacs, J. S., Y.-J. Jung, E. G. Mimnaugh, A. Martinez, F. Cuttita, and L. M. Neckers. 2002. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway. J. Biol. Chem. 277:29936-29944.
22. 2 sensing. Science 292:464-468.
23. Ivanov, S., S.-Y., Liao, A. Ivanova, A. Danilkovitch-Miagkova, N. Tarasova, G. Weirich, M. J. Merril, M. A. Proescholdt, E. H. Oldfield, J. Lee, J. Závada, A. Waheed, W. Sly, M. I. Lerman, and E. J. Stanbridge. 2001. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am. J. Pathol. 158:905-919.
24. Ivanov, S. V., I. Kuzmin, M.-H. Wei, S. Pack, L. Geil, B. E. Johnson, E. J. Stanbridge, and M. I. Lerman. 1998. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc. Natl. Acad. Sci. USA 95:12596-12601.
25. 2-regulated prolyl hydroxylation. Science 292:468-472.
26. Jongmans, W., K. van den Oudenalder, D. M. Tiemessen, J. Molkenboer, R. Willemsen, P. F. A. Mulders, and E. Oosterwijk. 2003. Targeting of adenovirus to human renal cell carcinoma cells. Urology 62:559-565.
27. Kaluz, S., M. Kaluzová, R. Opavský, S. Pastoreková, A. Gibadulinová, F. Dequiedt, R. Kettmann, and J. Pastorek. 1999. Transcriptional regulation of the MN/CA 9 gene coding for the tumor-associated carbonic anhydrase IX. Identification and characterization of a proximal silencer element. J. Biol. Chem. 274:32588-32595.
28. Kaluz, S., M. Kaluzová, A. Chrastina, P. L. Olive, S. Pastoreková, J. Pastorek, M. I. Lerman, and E. J. Stanbridge. 2002. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1α stabilization: a role for phosphatidylinositol 3′-kinase. Cancer Res. 62:4469-4477.
29. Kaluz, S., M. Kaluzová, and E. J. Stanbridge. 2003. Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia-responsive enhancer. Cancer Res. 63:917-922.
30. Kaluzová, M., S. Pastoreková, J. Pastorek, and S. Kaluz. 2000. P53 tumour suppressor modulates transcription of the TATA-less gene coding for the tumour-associated carbonic anhydrase MN/CAIX in MaTu cells. Biochim. Biophys. Acta 1491:20-26.
31. Kaluzová, M., S. Pastoreková, E. Svastová, J. Pastorek, E. J. Stanbridge, and S. Kaluz. 2001. Characterization of the MN/CA 9 promoter proximal region-a role for SP and AP1 factors. Biochem. J. 359:669-677.
32. Kern, S. E., J. A. Pietenpol, S. Thiagalingam, A. Seymour, K. W. Kinzler, B. Vogelstein. 1992. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830.
33. Koumenis, C., R. Alarcon, E. Hammond, P. Suthpin, W. Hoffman, M. Murphy, J. Derr, Y. Taya, S. W. Lowe, M. Kastan, and A. J. Giaccia. 2001. Regulation of p53 by hypoxia: dissociation of transcriptional repression and apoptosis from p53-dependent transactivation. Mol. Cell. Biol. 21:1297-1310.
34. Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299-303.
35. Lieskovská, J., M. Kaluzová, R. Opavsky′, S. Kaluz, J. Pastorek, R. Kettmann, and S. Pastoreková. 1998. Up-regulation of p53 by antisense expression of HPV 18 E6 oncogene does not influence the level of MN/CA IX tumor-associated protein in HeLa cervical carcinoma cells. Int. J. Oncol. 13:1081-1086.
36. Loncaster, J. A., A. L. Harris, S. E. Davidson, J. P. Logue, R. D. Hunter, C. C. Wykoff, J. Pastorek, P. J. Ratcliffe, I. J. Stratford, and C. M. L. West. 2001. Carbonic anhydrase (CAIX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 61:6394-6399.
37. Maxwell, P. H., M. Wiesener, G-W. Chang, S. Clifford, E. Vaux, M. Cockman, C. C. Wykoff, C. Pugh, E. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature (London) 399:271-275.
38. Pal, S., K. Datta, and D. Mukhopadhyay. 2001. Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma. Cancer Res. 61:6952-6957.
39. Post, D. E., and E. G. van Meir. 2001. Generation of bi-directional hypoxia/HIF-responsive expression vectors to target gene expression to hypoxic cells. Gene Ther. 8:1801-1807.
40. Ravi, R., B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng, L. E. Dillehay, A. Madan, G. L. Semenza, and A. Bedi. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14:34-44.
41. Salnikow, K., M. Costa, W. D. Figg, and M. V. Blagosklonny. 2000. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer. Cancer Res. 60:5630-5634.
42. Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer. 3:721-732.
43. Sheta, E. A., H. Trout, J. J. Gildea, M. A. Harding, and D. Theodorescu. 2001. Cell density mediated pericellular hypoxia leads to induction of HIF-1α via nitric oxide and Ras/MAP kinase mediated signaling pathways. Oncogene 20:7624-7634.
44. Stanbridge, E. J. 1981. Mycoplasma detection-an obligation to scientific accuracy. Isr. J. Med. Sci. 17:563-568.
45. Thomlinson, R., and L. Gray. 1955. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br. J. Cancer. 9:539-549.
46. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307-310.
47. 2 tension. Proc. Natl. Acad. Sci. USA 92:5510-5514.
48. Wykoff, C. C., N. J. Beasley, P. H. Watson, K. J. Turner, J. Pastorek, A. Sibtain, G. D. Wilson, H. Turley, K. L. Talks, P. H. Maxwell, C. W. Pugh, P. J. Ratcliffe, and A. L. Harris. 2000. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 60:7075-7083.
49. Wykoff, C. C., N. J. Beasley, P. H. Watson, L. Campo, S. K. Chia, R. English, J. Pastorek, W. S. Sly, P. J. Ratcliffe, and A. L. Harris. 2001. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am. J. Pathol. 158:1011-1019.
50. Závada, J., Z. Závadová, S. Pastoreková, F. Ciampor, J. Pastorek, and V. Zelník. 1993. Expression of MaTu-MN protein in human tumor cultures and in clinical specimens. Int. J. Cancer. 54:268-274.
51. Zhang, L., D. Yu, M. Hu, S. Xiong, A. Lang, L. M. Ellis, and R. E. Pollock. 2000. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. 60:3655-3661.
52. Zietz, C., M. Rossle, C. Haas, A. Sendelhofert, A. Hirschmann, M. Sturzl, and U. Lohrs. 1998. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. 153:1425-1433.